Ryman Healthcare stock was propelled to new trading highs yesterday after a record annual result by the retirement specialist.
Shares were selling for about $3.40 - eventually closing at $3.34 - after chairman David Kerr released what he called an exceptional result, the 10th in succession, telling shareholders how their dividends would rise 17 per cent to 8.4c a share for the year.
That was greeted by Deutsche Bank analysts James Schofield, Chris Byrne and Geoff Zame as a very solid result and they praised the company's momentum.
"We believe that Ryman will deliver on this guidance," they said after Kerr revealed development rates rose from an annual target of 550 units to 700 units "and we agree with their strategy of getting on and building while the rest of the sector, bar Summerset, is in a state of flux".
Before the result, Ryman, with a market capitalisation of $1.2 billion, had a 52-week trading range of $2.39 to $3.25.